Compare Adaptive Biotechnologies Corp (ADPT) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs ProShares Ultra QQQ ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while ProShares Ultra QQQ ETF trades at $89.72. Which is the better fit depends on your goals.
| ADPT | QLD | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $22.37 | $100.53 |
52-Week Low | $10.24 | $57.16 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
QLD, the ProShares Ultra QQQ ETF, trades at $93.12, up 2.8% today, reflecting strong bullish momentum with a technical buy signal from moving averages. As a 2x leveraged ETF tracking the Nasdaq-100, it amplifies returns but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though it experienced significant drawdowns historically.
The outlook for QLD is tied to tech sector strength, with AI optimism and easing geopolitical tensions supporting growth. However, leveraged ETFs like QLD are high-risk tactical instruments unsuitable for long-term holdings due to daily rebalancing effects. Investors should weigh potential amplified gains against the risk of sharp declines in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
